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Abstract. Background: The occurrence of radiological
mediastinal lymphadenopathy as the only evidence of tumor
recurrence of cervical carcinoma is very rare. We report on such
a case with stenosis of the esophagus. Case Report: A 36-year-
old Caucasian woman, without any relevant history of
gynecological cancer, underwent a trans-vaginal ultrasound with
evidence of any cervical lesion locally extended. After
histologically-proven diagnosis of squamous cell carcinoma of
the cervix uterine, the patient was treated by neoadjuvant
chemoradiation, followed by total abdominal hysterectomy with
bilateral salpingoophorectomy. A subsequent close follow-up was
negative for recurrence of disease until December 2008, two
years after diagnosis. At that period, the patient experienced
cough and severe dysphagia and for this reason she underwent
several examinations including esophagogastroduodenoscopy,
whole-body computed tomographic scan and bronchoscopy with
transbronchial needle aspiration. Histology led to diagnosis of
recurrence of cervical cancer, HPV31-positive, in multiple
mediastinal lymphnodes, with infiltration of the esophageal
mucosa. Conclusion: Mediastinal lymphade-nopathy in patients
with a history of cervical carcinoma should be suspicious of
metastatic disease, even if there is no radiological evidence of
distant metastases.
Cervical cancer ranks as the second most common
malignancy in women worldwide, with the majority (80% of
new cases) appearing in developing countries (1).
Approximately 80% of primary cervical carcinomas arise
from pre-existing squamous dysplasias (2). Despite
aggressive local therapy leading to excellent local control,
the incidence of distant metastases in patients with invasive
carcinoma of the uterine cervix is high (3). Approximately
70% of recurrences from cervical cancer are estimated to be
distant or a combination of local and distant metastases (4).
The incidence of metastases to other organs is 56%. The
most frequent sites are the lung, abdominal cavity, liver, and
gastrointestinal tract (3). Thoracic metastatic localization by
cervical cancer includes lung parenchyma, pleura, bronchial
tree, lymph nodes, lymphatics and chest wall (5). The
incidence of clinically-apparent lymph node involvement is
22%, mainly to para-aortic, supraclavicular, and inguinal
nodes (3). Few cases of isolated mediastinal lymph node
metastases from cervical cancer have been reported in the
literature (6-9), with no previous case describing an extensive
infiltration of the esophagus by mediastinal lymph node
metastases from cervical cancer recurrence. Distant
metastases are detected in clinically-advanced stages with
symptoms such as cough, hemoptysis, dysphagia and pain
(10), mimicking other neoplastic disease.
Case Report
A 36-year-old Caucasian woman, without any personal
clinical history of cancer, underwent a trans-vaginal
ultrasound in May 2007 which showed cervix echotexture
subverted by the presence of a polycyclic formation of
58×28×54 mm extending to the left side. To confirm the
lesion, the patient underwent a pelvic magnetic resonance
imaging (MRI) scan that documented an expansive lesion of
the uterine cervix of 5×4 cm, with spiculated and polycyclic
margins infiltrating the adipose tissue of both parametria.
Below, the lesion extended into the vagina with involvement
of the left fornix and, marginally, also of the right fornix.
Abdominal computed tomography (CT) scan confirmed the
expansive hypodense cervical lesion with a peripheral ring
of contrast enhancement and cervical margins preserved; it
also showed that the lesion displaced, without signs of
infiltration, the fundus bladder and the right juxta-vesical
urether. Endo-cervical biopsies of the lesion documented
squamous cell carcinoma with stromal invasion. From June
to July 2007 a neoadjuvant chemo-radiotherapy was
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performed. Multimodal treatment was performed with
intravenous cisplatin in continuous infusion. In August 2007,
the patient was evaluated by a pelvic MRI that showed a size
reduction of the lesion (25 mm vs. 50×40 mm) but the
extension in adipose tissue was more evident in the left
parametrium with vagina infiltration. Hysterectomy
according to Piver III was performed with bilateral
salpingectomy and bilateral pelvic lymphadenectomy.
Histological examination documented the absence of residual
tumor in both the left and right parametria, in fallopian tube
and in all 15 lymph nodes removed, with free vaginal
resection margins. Subsequent follow-up was negative until
December 2008 (15 months from diagnosis), until the
appearance of epigastric pain, orthodox dysphagia, cough,
vomiting and weight loss of 8 kg in three weeks.
Esophagogastroduodenoscopy showed gastroesophageal
reflux disease that was treated with esomeprazole and
domperidone without any clinical benefit. For this reason, in
February 2009, the patient came to the emergency room of
our hospital and was submitted to further
esophagogastroduodenoscopy that showed stenosis at 34 cm
from the dental arch. Staging with whole-body CT with
contrast scan confirmed the presence of the hypodense
esophageal tissue, with heterogeneous contrast enhancement
in the middle third and lower third of the esophagus, for a
cranio-caudal extension of about 10 cm. Critical stenosis
determined dilatation of the first third of esophagus and loss
of periesophageal planes of cleavage. Cleavage with the
ascending aorta was preserved (Figure 1). CT scan showed
subcentimetric lymph nodes in the right paratracheal and
precarinal side, and lomboaortic lymph nodes of about 
20 mm (Figure 2). The patient underwent fibrobroncoscopy
with transbronchial needle aspiration (TBNA) into retro-
carenal lymph node then cytological examination
documented neoplastic cells from cervix uterine neoplasm
positive for Human Papilloma Virus-31 (HPV31) (Figures 3-
4). Because of clinical worsening in dysphagia and cough,
the patient was submitted to Savary dilatation with
esophageal stenting. Moreover the patient was subjected to
first-line chemotherapy with cisplatin 75 mg/m2 on day 1
and vinorelbine 25 mg/m2 on day 1 and 8, every 21 days, for
two courses with good tolerance to treatment. In April 2009
(one year and eleven months after diagnosis), the patient
came to our attention with fever (38.5˚C) and persistent
productive cough. The CT scan documented alveolar filling
areas diffuse and widely confluent with aspects of ‘tree in
bud’ compatible with bronchopulmonary inflammation and
the presence of metastatic lymph nodes infiltrating the carina
with diameter of 2.5 mm, the paraesophageal area, the right
principal bronchus with 2.6 mm diameter. Considering this
pneumonia, the patient underwent antibiotic therapy with
improvement of the clinical status and CT scan. The third
cycle of chemotherapy was infused with a 25% dose
reduction for the altered performace status of patient. The
patient was evaluated with a whole-body CT scan after the
third cycle of chemotherapy. Staging of disease demonstrated
reduction of the flogistic areas in the right lower lobe, with
progressive disease in lymph nodes (17 mm) at the hepatic
hilum. The patient died one year after diagnosis of thoracic
recurrence.
Conclusion
The peculiarity of this case is associated with the pattern of
recurrence of cervical uterine cancer. Despite regular follow-
up, the patient experienced distant recurrence of disease that
ANTICANCER RESEARCH 34: 363-366 (2014)
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Figure 1. Chest scan: stenotic esophagus. Figure 2. Chest scan: mediastinal lymph node metastasis.
occurred with an important lesion determining severe
symptoms. Most recurrences from cervical cancer are
detected within 18 months after diagnosis, and the peak
period of detection is, generally, 9-12 months after diagnosis
(10). For this reason, it is very important to identify low- and
high-risk patients. In patients with early-stage cervical cancer
treated with radical surgery, adverse pathological factors, in
addition to nodal metastases, include larger tumour size,
deep cervical-stromal invasion, lymphovascular space
involvement, and extension to the vagina or parametria (11,
12). Large tumours are related to an higher risk of
extrapelvic disease, as well as to central recurrence after
treatment (13). Therefore, in our opinion, high-risk patients
should be accurately investigated with annual positron-
emission tomography (PET) with 18-F-fluorodeoxyglucose
(FDG), a technique that can detect early local or distant
recurrence (14-16). The importance of PET-FDG is provided
in current NCCN guidelines (2013). Moreover, the
gastrointestinal tract is a common site for both primary and
metastatic carcinomas and the differential diagnosis can be
hard to achieve, particularly when a metastatic tumor
involves the mucosal surface (17). Some studies have
demonstrated a correlation between the pathogenesis of
squamous cell carcinoma of the esophagus, head and neck
cancer and HPV infection (18, 19), but in this case, TBNA
of the lymph node showed that the cytological architecture in
metastasis was similar to the cellular architecture of the
primary tumor both positive for HPV31, suggesting a
lymphatic metastatic spread with esophageal infiltration.
Macroscopic evaluation during esophagogastroduodenoscopy,
showed a normal mucosa in the esophagus with ab estrinseco
infiltration.  In conclusion, mediastinal lymphadenopathy in
patients with a history of cervical carcinoma should be
considered suspicious for metastatic disease until proven
otherwise, even if there is no radiological evidence of other
distant metastases.
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